ProfileGDS5678 / 1445675_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 57% 56% 56% 56% 56% 58% 58% 56% 56% 56% 56% 56% 56% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5018657
GSM967853U87-EV human glioblastoma xenograft - Control 23.4156256
GSM967854U87-EV human glioblastoma xenograft - Control 33.4212656
GSM967855U87-EV human glioblastoma xenograft - Control 43.3400956
GSM967856U87-EV human glioblastoma xenograft - Control 53.37456
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6017258
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5887858
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4084356
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3959256
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4125156
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4123556
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3707156
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4365656
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4254556